17 unchanged sentences
Our financial statements are reported in USD and, accordingly, fluctuations in exchange rates will affect the translation of revenues and expenses denominated in foreign currencies into USD for purposes of reporting our consolidated financial results.
−Removed: During the years ended December 31, 2023 and 2022, the most significant currency exchange rate exposures were to the Euro and Chilean Peso.
+Added: During the years ended December 31, 2024 and 2023, the most significant currency exchange rate exposures were to the Chilean Peso and Euro.
Gross accumulated currency translation adjustments recorded as a separate component of shareholders’ equity were $52.7 million and $34.6 million at December 31, 2024 and 2023, respectively.
−Removed: For the years ended December 31, 2023 and 2022, fluctuations in exchange rates exposed us to additional foreign currency transaction risk, and we entered into a greater number of foreign exchange forward contracts than in the prior year.
For information on such open foreign exchange forward contracts for the years ended December 31, 2024 and 2023 see “Management’s Discussion and Analysis—Results of Operations— Foreign Currency Exchange Rates.”
5 unchanged sentences
Because of the short-term maturities of our investments, we do not believe that a change in market interest rates would have a significant negative impact on the value of our investment portfolio except for reduced interest income.
−Removed: At December 31, 2023, we had cash and cash equivalents of $95.9 million.
−Removed: The weighted average interest rate related to our cash and cash equivalents for the year ended December 31, 2023 was approximately 3.5%.
−Removed: As of December 31, 2023, the principal outstanding balances under BioReference’s Credit Agreement with CB and our Chilean and Spanish lines of credit was $25.3 million in the aggregate at a weighted average interest rate of approximately 7.52%.
−Removed: Our outstanding convertible senior and senior notes have fixed rates of interest;
−Removed: therefore, we are not exposed to interest rate rish on those instruments.
−Removed: See Note 7 and Note 22 to the audited consolidated financial statements contained in this Annual Report on Form 10-K.
−Removed: The primary objective of our investment activities is to preserve principal while at the same time maximizing yield without significantly increasing risk.
+Added: At December 31, 2024, we had cash, cash equivalents and restricted cash of $445.6 million.
+Added: The weighted average interest rate related to our cash, cash equivalents and restricted cash for the year ended December 31, 2024 was approximately 3.4%.
+Added: As of December 31, 2024, the principal outstanding balances under our Chilean and Spanish lines of credit was $13.5 million in the aggregate at a weighted average interest rate of approximately 5.52%.
+Added: As of December 31, 2024, the principal outstanding balance under our 2044 Notes, which accrue interest at the 3-month SOFR, was $250.0 million at a weighted average interest rate of approximately 12.98%.
+Added: Based on our outstanding balances at December 31, 2024, if our applicable interest rates on our variable rate debt increase by 1%, then our debt service on an annual basis would increase by approximately $2.5 million.
+Added: Our other outstanding convertible senior notes have fixed rates of interest;
+Added: therefore, we are not exposed to interest rate risk on those instruments.
+Added: See Note 7 to the audited consolidated financial statements contained in this Annual Report on Form 10-K.
+Added: The primary objective of our investment activities is to preserve the principal while at the same time maximizing yield without significantly increasing risk.
To achieve this objective, we may invest our excess cash in debt instruments of the U.S.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.